INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

Core Viewpoint - The ImmunityBio class action lawsuit alleges that the company and its Executive Chairman made misleading statements regarding the efficacy of its lead product, Anktiva, leading to significant stock price decline after regulatory scrutiny [3][4]. Company Overview - ImmunityBio, Inc. is a biotechnology company focused on developing next-generation immunotherapies, with Anktiva as its lead biologics product [2]. Allegations of the Lawsuit - The lawsuit claims that ImmunityBio made false statements about Anktiva, including unproven claims that it could make all NMIBC patients cancer-free long-term and mischaracterizing it as a cancer vaccine [3]. - A warning letter from the U.S. FDA highlighted that promotional materials misbranded Anktiva, suggesting it could cure and prevent all cancer, which raised public health concerns [4]. Stock Impact - Following the public disclosure of the FDA warning letter, ImmunityBio's stock price fell by 21% [4]. Legal Process - Investors who purchased ImmunityBio securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit, representing the interests of all class members [5].